Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
All conestat alfa studies
..
Feedback
Home
c19early.org COVID-19 treatment researchConestat alfaConestat alfa (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 conestat alfa studies

Home
@CovidAnalysis
All
Studies
Feedback
All studies   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -14% 2 121 Improvement, Studies, Patients Relative Risk Mortality -14% 2 121 Ventilation 17% 2 121 ICU admission -141% 1 83 Hospitalization 52% 1 38 RCTs -14% 2 121 RCT mortality -14% 2 121 Peer-reviewed -238% 1 83 Late -14% 2 121 Conestat alfa for COVID-19 c19early.org November 2025 Favorsconestat alfa Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 studies c19early.org November 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 mortality results c19early.org November 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 87% 0.13 [0.01-2.44] 0/27 2/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -286% 3.86 [0.51-29.3] 8/56 1/27 Tau​2​ = 4.17, I​2​ = 71.3%, p = 0.92 Late treatment 17% 0.83 [0.03-23.3] 8/83 3/38 17% lower risk All studies 17% 0.83 [0.03-23.3] 8/83 3/38 17% lower risk 2 conestat alfa COVID-19 mechanical ventilation results c19early.org November 2025 Tau​2​ = 4.17, I​2​ = 71.3%, p = 0.92 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PROTECT-COVID-19 Urwyler (RCT) -141% 2.41 [0.57-10.2] 10/56 2/27 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Late treatment -141% 2.41 [0.57-10.2] 10/56 2/27 141% higher risk All studies -141% 2.41 [0.57-10.2] 10/56 2/27 141% higher risk 1 conestat alfa COVID-19 ICU result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.24 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 52% 0.48 [0.22-1.04] hosp. time 27 (n) 11 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.063 Late treatment 52% 0.48 [0.22-1.04] 27 (n) 11 (n) 52% lower risk All studies 52% 0.48 [0.22-1.04] 27 (n) 11 (n) 52% lower risk 1 conestat alfa COVID-19 hospitalization result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.063 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 serious outcomes c19early.org November 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PROTECT-COVID-19 Urwyler (RCT) -117% 2.17 [0.81-5.79] no disch. 18/56 4/27 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.12 Late treatment -117% 2.17 [0.81-5.79] 18/56 4/27 117% higher risk All studies -117% 2.17 [0.81-5.79] 18/56 4/27 117% higher risk 1 conestat alfa COVID-19 recovery result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.12 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 Randomized Controlled Trials c19early.org November 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] 0/27 1/11 Improvement, RR [CI] Treatment Control PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] 7/56 1/27 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Late treatment -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk All studies -14% 1.14 [0.08-15.4] 7/83 2/38 14% higher risk 2 conestat alfa COVID-19 RCT mortality results c19early.org November 2025 Tau​2​ = 1.86, I​2​ = 50.5%, p = 0.93 Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.25 Late treatment -238% 3.38 [0.44-26.1] 7/56 1/27 238% higher risk All studies -238% 3.38 [0.44-26.1] 7/56 1/27 238% higher risk 1 conestat alfa COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.25 Effect extraction pre-specified(most serious outcome) Favors conestat alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Bernstein (SB RCT) 78% 0.22 [0.01-5.13] death 0/27 1/11 Improvement, RR [CI] Treatment Control Bernstein (SB RCT) 87% 0.13 [0.01-2.44] ventilation 0/27 2/11 Bernstein (SB RCT) 46% 0.54 [0.28-1.05] progression 12/27 9/11 Bernstein (SB RCT) 52% 0.48 [0.22-1.04] hosp. time 27 (n) 11 (n) PROTECT-COVID-19 Urwyler (RCT) -238% 3.38 [0.44-26.1] death 7/56 1/27 PROTECT-COVID-19 Urwyler (RCT) -889% 9.89 [0.58-169] death 6/56 0/27 PROTECT-COVID-19 Urwyler (RCT) -296% 3.96 [0.20-79.8] death 2/56 0/27 PROTECT-COVID-19 Urwyler (RCT) -286% 3.86 [0.51-29.3] ventilation 8/56 1/27 PROTECT-COVID-19 Urwyler (RCT) -141% 2.41 [0.57-10.2] ICU 10/56 2/27 PROTECT-COVID-19 Urwyler (RCT) -117% 2.17 [0.81-5.79] no disch. 18/56 4/27 Conestat alfa COVID-19 outcomes c19early.org November 2025 Favors conestat alfa Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0